Inhibrx (NASDAQ:INBX – Get Rating) had its target price dropped by JMP Securities from $40.00 to $35.00 in a research note issued to investors on Wednesday, Benzinga reports. The firm currently has a “market outperform” rating on the stock. JMP Securities’ target price would suggest a potential upside of 53.85% from the company’s previous close.
Separately, Credit Suisse Group dropped their target price on shares of Inhibrx from $48.00 to $46.00 and set an “outperform” rating on the stock in a report on Tuesday, November 8th.
Inhibrx Stock Down 2.5 %
NASDAQ INBX opened at $22.75 on Wednesday. The company has a debt-to-equity ratio of 3.54, a current ratio of 10.17 and a quick ratio of 6.05. The company’s 50 day simple moving average is $24.13 and its 200 day simple moving average is $24.87. Inhibrx has a 12 month low of $7.67 and a 12 month high of $34.72. The company has a market capitalization of $991.22 million, a P/E ratio of -6.28 and a beta of 2.96.
Insider Activity at Inhibrx
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. RA Capital Management L.P. acquired a new position in shares of Inhibrx during the 4th quarter worth $94,959,000. Perceptive Advisors LLC increased its stake in shares of Inhibrx by 50.8% during the 3rd quarter. Perceptive Advisors LLC now owns 2,887,860 shares of the company’s stock worth $51,837,000 after purchasing an additional 973,268 shares during the last quarter. BlackRock Inc. increased its stake in shares of Inhibrx by 10.8% during the 3rd quarter. BlackRock Inc. now owns 2,190,518 shares of the company’s stock worth $39,320,000 after purchasing an additional 213,407 shares during the last quarter. State Street Corp increased its stake in shares of Inhibrx by 282.7% during the 3rd quarter. State Street Corp now owns 2,040,054 shares of the company’s stock worth $36,619,000 after purchasing an additional 1,506,986 shares during the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Inhibrx by 8.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,467,918 shares of the company’s stock worth $26,348,000 after purchasing an additional 111,802 shares during the last quarter. Institutional investors and hedge funds own 72.79% of the company’s stock.
Inhibrx Company Profile
Inhibrx, Inc, a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcinoma; INBRX-105, a tetravalent conditional agonist of programmed death-ligand 1 and a conditional agonist of 4-1BB that is in Phase 1 clinical trials to treat patients with locally advanced or metastatic solid tumors; and INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.
- Get a free copy of the StockNews.com research report on Inhibrx (INBX)
- Fossil Group: Should You Bet On Consumer Discretionary In 2023?
- BJ’s Wholesale Club Stock Moves Higher After Strong Results
- Monthly Realty Income is About to Get Bigger
- 3 Large Cap Dividend Challengers for Millennial Investors
- Sea Ltd Is On The Verge Of A 100% Rally, Should You Buy?
Receive News & Ratings for Inhibrx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inhibrx and related companies with MarketBeat.com's FREE daily email newsletter.